The anti- XXXX activity of inulin in @entity19 .

@entity19 @entity465 @entity320 @entity1349
Finely divided, insoluble inulin (gamma polymorph), given intraperitoneally (i.p.) to C57BL @entity19 1-3 days after i.p. B16 @entity320 cells, very significantly increased their @entity1349 ( @entity1349 ) in low doses (less than or equal to 40 and less than or equal to 100 micrograms/ @entity19 in 50 and 80% of tests, respectively). The gamma inulin was pure and free of endotoxin and soluble inulin, and was developed as a potent reagent specific for activating the @entity465 ( @entity465 ). Its antitumour action paralleled its in vitro @entity465 activation, namely, both activities were sharply dose-dependent up to a threshold dose above which they were dose-independent; dissolved inulin was inactive in vitro and in vivo, decreased the @entity1349 of the @entity19 and in a mixture antagonized the in vitro and in vivo activities of gamma inulin; the more soluble (alpha) polymorphs were active in proportion to their gamma content but the effects were blocked at higher doses presumably by dissolved inulin. In addition, depletion of host @entity465 with cobra venom factor or inulin before giving B16 cells increased their malignancy and abrogated the subsequent antitumour action of gamma inulin. The minimum i.p. dose of gamma inulin found to activate serum @entity465 in vivo was 50 micrograms (2.5 mg/kg), i.e. close to the minimum antitumour dose. These close correlations and the specificity of the reagent indicate that activation in vivo of the @entity465 (cellular or humoral) is an important first contact in stimulating host antitumour defences in this @entity19 model.
